What are ‘evergreening’ and ‘thicketing’ and what is being done to reform the system and aid competition?
In recent years, pharmaceutical companies have become increasingly adept at exploiting the patent system in various ways, to delay competition from generic drug developers and extend their pricing monopolies. But what techniques are companies using and what is being done to crack down on them and reform the patent system?